Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial.
Germán ÁñezLisa M DunkleCynthia L GayKaren L KotloffJeffrey M AdelglassBrandon EssinkJames D CampbellShane Cloney-ClarkMingzhu ZhuJoyce S PlestedPavitra RoychoudhuryAlexander L GreningerNita PatelAlice McGarryWayne WooIksung ChoGregory M GlennFilip Dubovskynull nullPublished in: medRxiv : the preprint server for health sciences (2022)
NVX-CoV2373 was safe, immunogenic, and efficacious in the prevention of Covid-19 and those cases caused by the Delta variant in adolescents. (Funded by the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health; PREVENT-19 ClinicalTrials.gov number, NCT04611802 ).